Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
MASI Stock Summary
In the News
Is Masimo (MASI) Stock Outpacing Its Medical Peers This Year?
Here is how Masimo (MASI) and Addus HomeCare (ADUS) have performed compared to their sector so far this year.
Masimo (MASI) Plans Consumer Business Spin-Off to Drive Growth
Masimo (MASI) is evaluating a proposed separation of its consumer audio and consumer health product business in a bid to improve the profitability of the healthcare business.
Masimo (MASI) Soars 3.3%: Is Further Upside Left in the Stock?
Masimo (MASI) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Masimo CEO on potential split, proxy battle and spinning off consumer business
Joe Kiani, Masimo CEO, joins 'Closing Bell: Overtime' to discuss the company spinning off its consumer business.
Activist investor plans second fight at Masimo, sending shares up 12%
Quentin Koffey's Politan Capital waged a successful proxy fight at Masimo last year, and it is now seeking two more board seats.
Masimo's stock rallies on report of looming activist campaign, disclosure of spinoff plan
Masimo Corp.'s stock MASI, +1.40% was up 12% in premarket trading on Monday after The Wall Street Journal reported that activist investor Politan Capital Management plans to nominate two more members to the patient-monitoring technology company's board. Politan Capital, which was launched by Quentin Koffey, already has two seats on the company's board.
Masimo Stock Surges After Proposed Spinoff of Consumer Business
Share in Masimo (MASI) surged 13% in extended trading on Friday after the company announced that it is planning a spinoff of its consumer unit to improve the profitability of its primary healthcare business.
Activist investor Politan plans second proxy battle at Masimo, WSJ reports
Activist investor Politan Capital Management, which last year won two seats on the board of medical technology company Masimo Corp , is planning a second proxy battle for two more seats, the Wall Street Journal reported on Sunday.
Masimo plans to spinoff consumer business
Medical technology company Masimo Corp said on Friday it is evaluating a proposed spinoff of its consumer business, which includes its consumer health and audio products, sending shares up 13% in extended trading.
Here's Why You Should Add Masimo (MASI) to Your Portfolio Now
Masimo's (MASI) R&D activities raise optimism about the stock.
MASI Financial details
MASI Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-30
Metric | History | 2019-12-28 | 2021-01-02 | 2022-01-01 | 2022-12-31 | 2023-12-30 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 16.44 | 19.72 | 22.45 | 37.98 | 38.79 | |
Net income per share | 3.44 | 4.14 | 4.16 | 2.68 | 1.54 | |
Operating cash flow per share | 3.89 | 3.64 | 4.8 | 0.55 | 1.78 | |
Free cash flow per share | 2.61 | 2.26 | 4.16 | -0.5 | 0.12 | |
Cash per share | 12.06 | 11.06 | 13.5 | 3.79 | 3.14 | |
Book value per share | 20.47 | 24.27 | 28.08 | 24.98 | 25.85 | |
Tangible book value per share | 19.61 | 21.22 | 24.95 | 3.19 | -4.69 | |
Share holders equity per share | 20.47 | 24.27 | 28.08 | 24.98 | 25.85 | |
Interest debt per share | 0.36 | 0.6 | 0.6 | 18.68 | 18.46 | |
Market cap | 9.1B | 15.57B | 16.16B | 7.93B | 6.19B | |
Enterprise value | 8.55B | 14.96B | 15.45B | 8.7B | 6.99B | |
P/E ratio | 46.36 | 64.78 | 70.39 | 55.26 | 75.93 | |
Price to sales ratio | 9.7 | 13.61 | 13.04 | 3.9 | 3.02 | |
POCF ratio | 41.05 | 73.79 | 61.04 | 268.82 | 65.77 | |
PFCF ratio | 60.99 | 118.82 | 70.32 | -295.9 | 966.98 | |
P/B Ratio | 7.79 | 11.06 | 10.43 | 5.92 | 4.53 | |
PTB ratio | 7.79 | 11.06 | 10.43 | 5.92 | 4.53 | |
EV to sales | 9.12 | 13.08 | 12.47 | 4.27 | 3.41 | |
Enterprise value over EBITDA | 34.94 | 52.64 | 49.6 | 25.14 | 26.63 | |
EV to operating cash flow | 38.58 | 70.91 | 58.35 | 295 | 74.31 | |
EV to free cash flow | 57.33 | 114.19 | 67.22 | -324.72 | 1.09K | |
Earnings yield | 0.02 | 0.02 | 0.01 | 0.02 | 0.01 | |
Free cash flow yield | 0.02 | 0.01 | 0.01 | 0 | 0 | |
Debt to equity | 0.02 | 0.02 | 0.02 | 0.73 | 0.68 | |
Debt to assets | 0.01 | 0.02 | 0.02 | 0.3 | 0.3 | |
Net debt to EBITDA | -2.24 | -2.14 | -2.29 | 2.23 | 3.06 | |
Current ratio | 5.78 | 4.71 | 4.63 | 2.08 | 2.18 | |
Interest coverage | 674.44 | 756.87 | 776.96 | 8.17 | 3.27 | |
Income quality | 1.13 | 0.88 | 1.15 | 0.21 | 1.15 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0.32 | 0.3 | 0.31 | 0.32 | 0 | |
Research and developement to revenue | 0.1 | 0.1 | 0.11 | 0.09 | 0.09 | |
Intangibles to total assets | 0.04 | 0.1 | 0.09 | 0.36 | 0.53 | |
Capex to operating cash flow | -0.33 | -0.38 | -0.13 | -1.91 | -0.93 | |
Capex to revenue | -0.08 | -0.07 | -0.03 | -0.03 | -0.04 | |
Capex to depreciation | -3.09 | -2.73 | -0.98 | -0.41 | -0.89 | |
Stock based compensation to revenue | 0.04 | 0.04 | 0.04 | 0.02 | 0 | |
Graham number | 39.81 | 47.57 | 51.27 | 38.79 | 29.96 | |
ROIC | 0.15 | 0.16 | 0.14 | 0.07 | 0.07 | |
Return on tangible assets | 0.15 | 0.16 | 0.13 | 0.07 | 0.06 | |
Graham Net | 10.81 | 9.49 | 11.95 | -20.22 | -17.47 | |
Working capital | 823.84M | 867.33M | 970.68M | 678.6M | 668.1M | |
Tangible asset value | 1.12B | 1.23B | 1.38B | 170.9M | -247.5M | |
Net current asset value | 767.81M | 796.25M | 901.65M | -563.1M | -444.8M | |
Invested capital | 0.02 | 0.02 | 0.02 | 0.73 | 0.68 | |
Average receivables | 121.03M | 136.89M | 171.06M | 323.33M | 433.45M | |
Average payables | 47.47M | 59.3M | 69.84M | 176.21M | 264.15M | |
Average inventory | 104.81M | 165.91M | 208.66M | 351.19M | 523M | |
Days sales outstanding | 51.54 | 45.11 | 59.14 | 79.95 | 75.03 | |
Days payables outstanding | 64.5 | 58.36 | 64.07 | 103.41 | 87.88 | |
Days of inventory on hand | 137.02 | 196.72 | 170.61 | 187.17 | 190.43 | |
Receivables turnover | 7.08 | 8.09 | 6.17 | 4.57 | 4.86 | |
Payables turnover | 5.66 | 6.25 | 5.7 | 3.53 | 4.15 | |
Inventory turnover | 2.66 | 1.86 | 2.14 | 1.95 | 1.92 | |
ROE | 0.17 | 0.17 | 0.15 | 0.11 | 0.06 | |
Capex per share | -1.27 | -1.38 | -0.63 | -1.05 | -1.66 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-30 for Q4
Metric | History | 2022-12-31 | 2023-04-01 | 2023-07-01 | 2023-09-30 | 2023-12-30 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 11.75 | 10.74 | 8.62 | 9.07 | 10.4 | |
Net income per share | 0.78 | 0.4 | 0.3 | 0.2 | 0.64 | |
Operating cash flow per share | -0.13 | 0.01 | 0.45 | -0.13 | 1.46 | |
Free cash flow per share | -0.25 | -0.34 | 0.03 | -0.55 | 0.98 | |
Cash per share | 3.86 | 3.31 | 2.85 | 2.36 | 3.14 | |
Book value per share | 25.5 | 25.29 | 24.78 | 24.16 | 25.85 | |
Tangible book value per share | 3.26 | 4.16 | 4.39 | 4.65 | -4.69 | |
Share holders equity per share | 25.5 | 25.29 | 24.78 | 24.16 | 25.85 | |
Interest debt per share | 19.81 | 18.32 | 17.99 | 18.54 | 17.77 | |
Market cap | 7.77B | 9.71B | 8.69B | 4.63B | 6.19B | |
Enterprise value | 8.59B | 10.43B | 9.43B | 5.42B | 6.99B | |
P/E ratio | 47.48 | 113.93 | 138.35 | 109.19 | 45.64 | |
Price to sales ratio | 12.59 | 17.18 | 19.08 | 9.67 | 11.27 | |
POCF ratio | -1.18K | 24.27K | 368.15 | -661.36 | 80.27 | |
PFCF ratio | -597.49 | -545.33 | 5.79K | -159.09 | 119.47 | |
P/B Ratio | 5.8 | 7.3 | 6.64 | 3.63 | 4.53 | |
PTB ratio | 5.8 | 7.3 | 6.64 | 3.63 | 4.53 | |
EV to sales | 13.93 | 18.46 | 20.7 | 11.31 | 12.74 | |
Enterprise value over EBITDA | 55.95 | 162.72 | 172.96 | 85.01 | 80.01 | |
EV to operating cash flow | -1.3K | 26.08K | 399.42 | -773.6 | 90.7 | |
EV to free cash flow | -661.02 | -585.97 | 6.28K | -186.09 | 134.99 | |
Earnings yield | 0.01 | 0 | 0 | 0 | 0.01 | |
Free cash flow yield | 0 | 0 | 0 | -0.01 | 0.01 | |
Debt to equity | 0.77 | 0.72 | 0.72 | 0.76 | 0.68 | |
Debt to assets | 0.32 | 0.31 | 0.31 | 0.32 | 0.3 | |
Net debt to EBITDA | 5.38 | 11.29 | 13.54 | 12.33 | 9.2 | |
Current ratio | 2.08 | 2.16 | 2.11 | 2.14 | 2.18 | |
Interest coverage | 6.43 | 3.22 | 2.48 | 1.97 | 4.7 | |
Income quality | -0.16 | 0.02 | 1.5 | -0.66 | 2.27 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0.57 | 0.04 | 0 | 0 | |
Sales general and administrative to revenue | 0.28 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0.09 | 0.09 | 0.09 | 0.1 | 0.07 | |
Intangibles to total assets | 0.36 | 0.36 | 0.36 | 0.34 | 0.53 | |
Capex to operating cash flow | 0.97 | -45.5 | -0.94 | 3.16 | -0.33 | |
Capex to revenue | -0.01 | -0.03 | -0.05 | -0.05 | -0.05 | |
Capex to depreciation | -0.08 | -0.7 | -0.88 | -0.9 | -1.12 | |
Stock based compensation to revenue | 0.01 | 0.01 | -0.02 | 0 | 0.02 | |
Graham number | 21.14 | 15.18 | 12.88 | 10.45 | 19.32 | |
ROIC | 0.02 | 0.01 | 0.01 | 0.01 | 0.04 | |
Return on tangible assets | 0.02 | 0.01 | 0.01 | 0.01 | 0.02 | |
Graham Net | -19.8 | -19.98 | -19.3 | -19.62 | -17.47 | |
Working capital | 678.6M | 677.6M | 636.3M | 658.7M | 668.1M | |
Tangible asset value | 170.9M | 218.6M | 231.7M | 245.5M | -247.5M | |
Net current asset value | -563.1M | -524.4M | -494.7M | -482.8M | -444.8M | |
Invested capital | 0.77 | 0.72 | 0.72 | 0.76 | 0.68 | |
Average receivables | 438.35M | 458.15M | 380M | 352.85M | 388.95M | |
Average payables | 272.3M | 262.95M | 257.3M | 274.5M | 267.5M | |
Average inventory | 498.2M | 502.25M | 523.05M | 563.6M | 564.8M | |
Days sales outstanding | 73.68 | 65.5 | 68.95 | 67.07 | 69.03 | |
Days payables outstanding | 82.06 | 80.01 | 102.07 | 104.53 | 79.09 | |
Days of inventory on hand | 148.52 | 161.72 | 208.6 | 215.54 | 171.38 | |
Receivables turnover | 1.22 | 1.37 | 1.31 | 1.34 | 1.3 | |
Payables turnover | 1.1 | 1.12 | 0.88 | 0.86 | 1.14 | |
Inventory turnover | 0.61 | 0.56 | 0.43 | 0.42 | 0.53 | |
ROE | 0.03 | 0.02 | 0.01 | 0.01 | 0.02 | |
Capex per share | -0.12 | -0.35 | -0.42 | -0.42 | -0.48 |
MASI Frequently Asked Questions
What is Masimo Corporation stock symbol ?
Masimo Corporation is a US stock , located in Irvine of Ca and trading under the symbol MASI
Is Masimo Corporation buy or a sell ?
13 stock analysts have 13 predictions with a medium analyst target price of $161.46. The lowest prediction is $130 and the highest is $207
What is MASI stock prediction ?
With a median analyst target price of $158, 3 stock analysts have made 3 forecasts in last 90 days. $148 is the lowest and $166 is the greatest projection.
What is Masimo Corporation stock quote today ?
Masimo Corporation stock price is $146.69 today.
Is Masimo Corporation stock public?
Yes, Masimo Corporation is a publicly traded company.